BacScience Research Reference

MIC (Methionine + Inositol + Choline) Reconstitution & Research Reference

MIC is a non-peptide combination commonly referring to methionine, inositol and choline. The term describes a formulation family rather than one universally standardized drug product. This research reference examines MIC composition, concentration, reconstitution and diluent considerations, stability, sterile quality, endotoxin risk, regulatory context and the limits of human clinical evidence.

Chemical structure of methionine
Methionine molecular structure. Source: Wikimedia Commons, public-domain chemical structure.
Compound MIC
Full name Methionine + Inositol + Choline
Chemical class Amino acid + cyclic polyol + quaternary ammonium nutrient
Common documented strength 25 / 50 / 50 mg/mL
Research applications Lipid metabolism, methylation, membrane biology
Human evidence Limited for the modern MIC injection blend
Regulatory status Formulation and jurisdiction dependent
Last reviewed September 2026

MIC Reconstitution & Concentration: Quick Answer

Does MIC commonly require reconstitution? Not necessarily. Many documented MIC formulations are supplied as finished aqueous solutions rather than as lyophilized powders requiring reconstitution.

Is there one standardized MIC formulation? No. MIC is a descriptive name for a combination of methionine, inositol and choline. Concentrations, salts, preservatives, additional vitamins and intended routes can vary between formulations.

Is bacteriostatic water an established universal MIC diluent? No. A universal BAC-water reconstitution procedure cannot be established from the available authoritative evidence.

What determines MIC concentration? Concentration is determined independently for each component by its mass divided by the final solution volume.

What should researchers verify? The exact composition, salt form, material grade, formulation, preservative system, diluent, final concentration, sterility, endotoxin specification and validated storage conditions.

MIC Research Snapshot

MIC should be evaluated as a formulation rather than assumed to be a single standardized pharmaceutical compound.

MIC

RECONSTITUTION

Many MIC products are already aqueous solutions. Reconstitution is therefore formulation-dependent rather than an inherent requirement of MIC itself.

D

DILUENT

No universal BAC-water recommendation is established. The exact product or validated formulation documentation should determine the diluent.

C

CONCENTRATION

A commonly documented MIC concentration is 25/50/50 mg/mL for methionine, inositol and choline, but this should not be treated as a universal standard.

Q

QUALITY

Ingredient identity, grade, assay, impurities, preservative system, sterility and endotoxin controls should be evaluated separately.

E

CLINICAL EVIDENCE

Human evidence exists for some lipotropic combinations and individual components, but evidence for modern compounded MIC injections is limited.

R

REGULATORY STATUS

MIC should not be presented as an FDA-approved weight-loss drug. Regulatory status depends on the exact formulation, route and jurisdiction.

What Is MIC?

MIC commonly refers to a combination of L-methionine, inositol and choline. In injectable compounding contexts, choline is commonly supplied as a choline salt, such as choline chloride.

The three components belong to different chemical and biological categories. Methionine is a sulfur-containing amino acid; myo-inositol is a cyclitol involved in cell signaling and membrane-related biology; and choline is an essential nutrient and precursor for phospholipid and neurotransmitter pathways.

The name MIC does not identify one exact pharmaceutical formulation. Published and regulatory documents show examples of formulations at approximately 25 mg/mL methionine, 50 mg/mL inositol and 50 mg/mL choline, while other formulations add vitamin B12, B-complex vitamins, lidocaine or other ingredients.

MIC Molecular Identity

Component Common chemical identity Molecular formula Approx. molecular weight
Methionine L-Methionine C₅H₁₁NO₂S 149.21 g/mol
Inositol myo-Inositol C₆H₁₂O₆ 180.16 g/mol
Choline Common injectable form: choline chloride C₅H₁₄ClNO 139.62 g/mol
Chemical structure of choline
Choline structural diagram. Source: Wikimedia Commons, public-domain chemical structure.

How Does MIC Function Biologically?

Methionine

Methionine is an essential sulfur-containing amino acid and precursor to S-adenosylmethionine (SAM), an important methyl-group donor in numerous biochemical reactions.

Methionine metabolism also intersects with homocysteine and transsulfuration pathways.

Inositol

Myo-inositol participates in phosphoinositide signaling and is a structural component of membrane-associated cellular signaling pathways.

Choline

Choline contributes to phosphatidylcholine synthesis, methyl-group metabolism and acetylcholine production.

The Combination

The three nutrients participate in related metabolic and lipid pathways, but mechanistic plausibility should not be confused with clinical proof that an injectable MIC combination produces weight loss or other therapeutic outcomes.

What Is MIC Being Studied For?

Lipid Metabolism

Methionine and choline are involved in hepatic lipid handling and methylation-related pathways that have been investigated in metabolic research.

Liver Biology

Choline is important for hepatic phospholipid metabolism, while methionine participates in methylation and sulfur-amino-acid metabolism.

Cell Signaling

Inositol-containing phospholipids participate in intracellular signaling and membrane biology.

Nutritional Research

Each component has an established nutritional and biochemical research history independent of compounded injectable MIC products.

Lipotropic Formulations

MIC has historically been incorporated into lipotropic formulations, although evidence for modern injectable weight-management claims remains limited.

Combination Research

Historical studies have investigated lipotropic combinations, but modern MIC injectable formulations are not standardized clinical products.

Human Clinical Research

The evidence base for MIC requires careful separation between component-level research, historical oral lipotropic products and modern compounded injectable formulations.

Evidence-level warning:

Human studies involving methionine, inositol and choline do not automatically demonstrate efficacy of a contemporary 25/50/50 mg/mL MIC injection for weight loss, fat reduction, energy or other wellness claims.

Research Type What Has Been Studied Interpretation
Historical lipotropic trials Methionine, inositol and choline combinations Historical evidence; formulations and indications differ from modern compounded MIC injections.
Component research Methionine, myo-inositol and choline individually Useful for understanding biological pathways but does not prove combination-injection efficacy.
Modern MIC injection Compounded formulations No standardized FDA-reviewed MIC drug product or universal dose-finding evidence.

PubMed indexes historical controlled clinical research involving lipotropic combinations of methionine, inositol and choline. One example is the 1974 “Lipotriad” double-blind clinical trial. The existence of these historical studies does not establish efficacy for today's compounded MIC injection formulations.

Routes Studied

Route Research Context Evidence Interpretation
Oral Nutritional and historical lipotropic research Most component-level evidence is nutritional or oral rather than based on injectable MIC.
Intramuscular Compounded MIC formulations Used in some compounded formulations, but there is no universal standardized MIC product.
Subcutaneous Some modern compounded formulations Formulation-specific; evidence cannot be transferred from another route automatically.
Intravenous Some compounded nutrient formulations Requires route-specific sterile formulation, compatibility and quality controls.

MIC Reconstitution Research

MIC does not have a universal reconstitution procedure.

Many documented MIC formulations are supplied as finished aqueous solutions rather than lyophilized powders.

Consequently, the first question should not be: “How much BAC water should be added to MIC?”

The first question should be: “What exact MIC formulation is being evaluated, and is it supplied as a finished solution or as a material requiring preparation?”

Before Any Preparation, Verify

  • Exact component names
  • Methionine stereochemistry and grade
  • Inositol identity
  • Choline salt
  • Whether B12 or other ingredients are present
  • Existing solution versus dry material
  • Labeled concentration
  • Intended route
  • Specified diluent
  • Sterility and endotoxin specifications

Do Not Assume

  • All MIC products have the same strength
  • All MIC products contain the same choline salt
  • MIC is always a powder
  • MIC always needs reconstitution
  • BAC water is automatically compatible
  • A supplement-grade ingredient is suitable for injection
  • A COA proves sterility
  • One formulation's storage data applies to another

MIC Diluent Considerations

Available formulation documentation demonstrates that sterile water, water-for-injection systems and preserved aqueous formulations can occur in MIC-related compounding. This does not establish one universal diluent.

Question Research Conclusion
Is BAC water universally established for MIC? No
Is sterile water used in documented formulations? Yes, formulation-specific examples exist.
Is bacteriostatic water documented for some compounded MIC formulations? Yes, some compounding records describe preserved WFI systems, but this does not create a universal recipe.
Does diluent compatibility establish stability? No
Should the formulation documentation control? Yes

A stability-indicating assay project evaluated a compounded MIC injectable containing L-methionine 25 mg/mL, inositol 50 mg/mL and choline chloride 50 mg/mL with benzyl alcohol and WFI or SWFI as inactive ingredients. This is useful formulation evidence, but it should not be converted into a universal preparation instruction for unrelated MIC products.

MIC Concentration Calculations

MIC is a multi-component formulation, so each component has its own concentration.

Component concentration (mg/mL) = component amount (mg) ÷ final solution volume (mL)

For a documented example concentration of methionine 25 mg/mL + inositol 50 mg/mL + choline 50 mg/mL , a finished 10 mL volume mathematically contains:

  • Methionine: 250 mg total
  • Inositol: 500 mg total
  • Choline: 500 mg total

At the same labeled concentration, a 30 mL finished volume mathematically corresponds to:

  • Methionine: 750 mg total
  • Inositol: 1,500 mg total
  • Choline: 1,500 mg total

These are concentration calculations only. They do not instruct a user to prepare, dilute, inject or administer MIC.

Open Universal BAC Water Calculator
Important calculator limitation

The BacScience Universal BAC Water Calculator performs mathematical concentration and volume conversions. It does not determine whether bacteriostatic water is chemically compatible with MIC, whether a formulation is sterile, whether endotoxin levels are acceptable, whether a solution is stable or whether a particular route is medically appropriate.

MIC Vial Quantity & Concentration

Vial size and concentration are different specifications. A 10 mL vial and a 30 mL vial can contain the same concentration while containing different total quantities of each component.

Example Finished Volume Methionine Inositol Choline Combined Mass
1 mL 25 mg 50 mg 50 mg 125 mg
10 mL 250 mg 500 mg 500 mg 1,250 mg
30 mL 750 mg 1,500 mg 1,500 mg 3,750 mg

These figures are mathematical examples based on the 25/50/50 mg/mL formulation and should not be interpreted as a universal MIC product specification.

MIC Stability & Storage Research

Stability should be evaluated for the complete formulation rather than inferred from the stability of methionine, inositol or choline individually.

Chemical Stability

  • Concentration may change if water loss or evaporation occurs.
  • pH can influence formulation stability.
  • Light and temperature may affect individual components or the complete formulation.
  • Preservatives can influence microbiological stability but do not replace appropriate sterile manufacturing controls.
  • Stability claims should be supported by formulation-specific data.

Storage

  • Follow the exact product label or validated formulation record.
  • Do not transfer storage claims from one MIC product to another.
  • Finished liquid formulations may have storage requirements that differ from dry raw materials.
  • Reconstituted or diluted material may have a different stability profile from the original formulation.

Sterility & Endotoxin Considerations

If MIC is being evaluated as an injectable preparation, chemical purity alone is insufficient. Sterility, endotoxin control, aseptic processing, container closure and appropriate ingredient quality are separate considerations.

Sterile quality is formulation-specific.

FDA inspection records have documented MIC injectable products and have also identified deficiencies involving sterile-product testing and ingredient quality in compounding facilities. These records illustrate why the presence of a familiar 25/50/50 formulation does not by itself establish that a particular vial is sterile or suitable for administration.

FDA states that compounders should know the identity and quality of their bulk drug substances and excipient suppliers and should understand the testing performed on those components.

Sterility Questions

  • Was the product manufactured under appropriate sterile conditions?
  • Was sterility testing performed using a suitable method?
  • Is the container closure appropriate?
  • Is the product single-dose or multi-dose?
  • Is the preservative system documented?

Endotoxin Questions

  • Is there an applicable endotoxin specification?
  • Was endotoxin testing performed?
  • Is the test method appropriate for the matrix?
  • Is the raw-material source traceable?
  • Does the finished product have appropriate quality documentation?

MIC Quality & Purity Considerations

Identity

Confirm methionine, inositol and the exact choline salt rather than treating all “MIC” labels as chemically identical.

Assay

Evaluate the measured concentration of each component independently.

Material Grade

Research, food, dietary-supplement and pharmaceutical grades should not be treated as interchangeable.

Endotoxin

Injectable research requires appropriate endotoxin controls. High chemical purity alone does not establish endotoxin suitability.

Sterility

A COA reporting assay or purity does not independently prove finished product sterility.

Traceability

Maintain lot number, manufacturer, analytical method, source and formulation records.

MIC Regulatory Status

MIC should not be described as a single FDA-approved drug. The term generally refers to compounded combinations of methionine, inositol and choline, sometimes with additional ingredients.

FDA records demonstrate that MIC formulations have existed in compounded sterile products, including documented 25/50/50 mg/mL formulations. However, the existence of a compounded formulation is not equivalent to FDA approval of the combination for weight loss or general wellness.

FDA's compounding framework also places requirements and limitations on bulk drug substances used by 503A and 503B compounders. FDA emphasizes supplier qualification, certificates of analysis and applicable USP/NF requirements where relevant.

Regulatory distinction:

“Compounded,” “research use,” “dietary supplement,” and “FDA-approved drug” are different regulatory categories and should not be used interchangeably.

Safety Findings

Safety depends on the individual component, concentration, formulation, route, patient characteristics and manufacturing quality.

  • Methionine participates in methylation and sulfur metabolism, and excessive intake can alter homocysteine metabolism.
  • Choline has established nutritional functions but excessive exposure can produce adverse effects depending on dose and route.
  • Inositol is generally well characterized as a nutritional compound, but injectable formulations introduce additional formulation-specific considerations.
  • Injection introduces risks that do not apply in the same manner to oral supplementation, including microbial contamination, endotoxin exposure and formulation errors.
  • The presence of three familiar nutrients does not automatically make a compounded injection clinically validated.

MIC and Weight-Loss Research

Mechanistic plausibility is not clinical proof.

MIC is frequently marketed as a “lipotropic” injection for weight management. However, the evidence supporting this claim should be separated from the extensive biochemical literature on the individual nutrients.

Methionine, inositol and choline each have biological roles associated with lipid metabolism or related pathways. That does not establish that injecting the three compounds together produces clinically meaningful weight loss.

Researchers should therefore distinguish: component biology → historical combination research → modern compounded MIC formulation → clinical efficacy evidence.

Research Limitations

  • MIC is not one standardized molecular entity.
  • Formulations can differ in salt form, concentration, preservatives and added ingredients.
  • Modern compounded MIC injections have limited direct clinical evidence.
  • Historical lipotropic research should not be treated as equivalent to modern injectable MIC research.
  • Evidence for individual components cannot automatically be transferred to the combination.
  • Evidence from one route cannot automatically be transferred to another.
  • Mathematical concentration calculations do not establish chemical compatibility or clinical suitability.

Frequently Asked Questions About MIC

What does MIC stand for?

MIC commonly stands for methionine, inositol and choline. In injectable formulations, choline is often supplied as choline chloride.

What is the common MIC concentration?

A commonly documented compounded formulation contains methionine 25 mg/mL, inositol 50 mg/mL and choline 50 mg/mL. This is an example rather than a universal MIC standard.

Does MIC require reconstitution?

Not necessarily. Many documented MIC products are supplied as finished aqueous solutions. Whether preparation or reconstitution is required depends on the exact formulation.

Can MIC be reconstituted with bacteriostatic water?

Bacteriostatic water should not be assumed to be a universal MIC diluent. The exact formulation documentation should establish whether a diluent is required and which diluent is compatible.

How is MIC concentration calculated?

Each component is calculated separately using component mass divided by final solution volume. For example, 250 mg of methionine in a 10 mL final volume equals 25 mg/mL.

What is a 25/50/50 MIC formulation?

It commonly refers to 25 mg/mL methionine, 50 mg/mL inositol and 50 mg/mL choline. The exact chemical identity and formulation should still be verified from the product documentation.

Is MIC FDA approved for weight loss?

MIC as a compounded methionine/inositol/choline combination should not be presented as an FDA-approved weight-loss drug.

Does research on methionine prove MIC injections work?

No. Research on an individual component does not establish efficacy for a multi-component injectable formulation.

Does a MIC certificate of analysis prove sterility?

Not necessarily. A COA can contain identity, assay or purity data, while sterility and endotoxin require appropriate separate controls and testing.

Can MIC be used as a research concentration calculator?

Yes. Concentration can be calculated mathematically for each component, but the calculation does not determine compatibility, sterility, stability or appropriate administration.

What is the difference between MIC and MIC+B12?

Basic MIC refers to methionine, inositol and choline. MIC+B12 adds vitamin B12, commonly cyanocobalamin or another specified B12 form. The exact concentration and formulation must be verified from the product label.

Calculate MIC Concentration Mathematically

Use the BacScience Universal BAC Water Calculator for mathematical concentration and volume conversions. Remember that the calculator does not determine diluent compatibility, sterility, endotoxin safety, stability or clinical suitability.

Open Universal BAC Water Calculator

Scientific & Regulatory References

  1. U.S. Food & Drug Administration — FDA Form 483 documenting a MIC methionine/inositol/choline 25/50/50 mg/mL injectable formulation.
  2. U.S. Food & Drug Administration — FDA Form 483 documenting MIC 25/50/50 mg/mL and MIC with cyanocobalamin 25/50/50/1 mg/mL formulations.
  3. U.S. Food & Drug Administration — Bulk Drug Substances Used in Compounding Under Section 503B.
  4. U.S. Food & Drug Administration — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated 2026.
  5. PubMed — Lipotriad. A double-blind clinical trial.
  6. PubMed — Historical clinical research involving methionine, inositol and choline lipotropic combinations.
  7. Stability-indicating analytical research of a compounded MIC injectable containing L-methionine 25 mg/mL, inositol 50 mg/mL and choline chloride 50 mg/mL.

Last Reviewed

September 11, 2026

MIC formulations, sterile-compounding requirements, regulatory documents and clinical evidence should be periodically re-evaluated as new information becomes available.

Research information only. This page is provided for scientific and educational reference. It is not medical advice, prescribing guidance or a substitute for a validated pharmaceutical formulation. MIC refers to a family of formulations rather than one standardized drug product. Do not use the mathematical examples on this page as instructions for preparation, injection or human administration. Injectable formulations require appropriate professional evaluation, validated formulation procedures and applicable sterile compounding requirements.